Shanghai Pharmaceutical (02607): ANDA for etrapopar tablets was approved by the US FDA

Zhitongcaijing · 1d ago

Zhitong Financial App News, Shanghai Pharmaceutical (02607) issued an announcement. Recently, Changzhou Pharmaceutical Co., Ltd. (hereinafter referred to as “Changzhou Pharmaceutical Factory”), a subsidiary of Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”), received a notice from the US Food and Drug Administration (hereinafter referred to as “the US FDA”). The simplified new drug application (“ANDA”, the US generic drug application) has been approved for listing.

Etripopar tablets are mainly used for chronic immune (idiopathic) thrombocytopenia and severe aplastic anemia. They were first developed by Novartis and marketed in the US in 2008. In September 2025, Changzhou Pharmaceutical Co., Ltd. submitted an ANDA application to the US FDA for this drug, which was recently approved for marketing. As of the date of this announcement, the company has invested approximately RMB 9.8777 million in R&D expenses for this drug.

This time, Changzhou Pharmaceutical Co., Ltd.'s ANDA for etrapopa tablets was approved by the US FDA, which is of positive significance for the company to further expand overseas markets and has accumulated valuable experience.